Drug Profile
Cerebroside sulfatase - Takeda
Alternative Names: Arylsulfatase A; HGT-1110; HGT-1111; Metazym; Recombinant human arylsulfatase A; Recombinant human cerebroside sulfatase; Recombinant human sulfatidate sulfatase; rhASA; SHP-611; Sulfatide sulfatase; TAK 611Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Zymenex A/S
- Developer Assistance Publique Hopitaux de Paris; Takeda; Zymenex A/S
- Class Arylsulfatases; Recombinant proteins
- Mechanism of Action Cerebroside sulfatase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Metachromatic leukodystrophy
Most Recent Events
- 25 Apr 2022 Cerebroside sulfatase is still in phase II trial for metachromatic leukodystrophy in USA, the UK, Japan, Italy, Greece, Argentina, the Netherlands, Belgium, Brazil, Canada, France, Germany, Israel, Mexico and Spain (EudraCT2018-003291-12; NCT03771898)
- 02 Apr 2022 Pooled efficacy data from rhASA-01, rhASA-03 and rhASA-05 trials in Metachromatic leukodystrophy presented at the 74th Annual Meeting of the American Academy of Neurology 2022 (AAN-2022)
- 01 Apr 2022 Phase-II clinical trials in Metachromatic leukodystrophy (In children) in Argentina (Intrathecal) (NCT03771898) (EudraCT2018-003291-12)